Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 104 participants.

Also called NCT01472926

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 104 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01472926
  • EudraCT 2010-024541-67
Other papers using this trial's data
  • Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study The Lancet. Neurology, 2015-04 DOI, PubMed 25726502
  • Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke Stroke, 2015-12 DOI, PubMed 26514192
  • Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke: Analysis of 2 Randomized Controlled Trials Circulation, 2017-01-31 DOI, PubMed 27965285

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01472926. Randomized; single masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2013-12-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis- (ATTEST)
Acronym
ATTEST
Condition
Stroke
Intervention (Drug)
Tenecteplase
Intervention (Drug)
alteplase
Lead sponsor
NHS Greater Glasgow and Clyde (class: other)
Collaborator
University of Glasgow (class: other)

Record details

Record id
cardio:ct-nct01472926
Content hash
0c7d9ef445319fbd7dc95ca5f77746eb10be6a1ab575b7fa598a9ade1f970323